Prognosis and Biology of Postpartum Breast Cancer: A Protocol for Meta-Analysis of Survival and Systematic Review of the Tumour Micro-environment | ||
| Journal of Integrated Maternal and Pediatric Care | ||
| Volume 9, Issue 1, September 2026, Pages 53-59 PDF (255.68 K) | ||
| Document Type: Protocol | ||
| DOI: 10.18502/jimpc.v9i1.22985 | ||
| Authors | ||
| Samane Heydari* 1; Sadegh Safaei2, 3; Masoumeh Dehghan Manshadi3; Marzieh Naseri4; Arefeh Dehghani-Tafti1, 5 | ||
| 1Mother and Newborn Health Research Center, Comprehensive Research Institute for Maternal and Child Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran | ||
| 2Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran | ||
| 3Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran | ||
| 4Department of Developmental, Molecular, and Chemical Biology, Tufts University School of Medicine, Boston, MA, United States | ||
| 5Department of Biostatistics, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran | ||
| Abstract | ||
| Postpartum breast cancer (PPBC) is associated with poorer survival, higher metastatic rates, and distinct tumor biology versus breast cancer in nulliparous women or those with a longer delivery interval. Lactation, weaning, and postpartum mammary involution may create a pro-metastatic mi-croenvironment, but evidence linking these exposures to prognosis and tumor-immune-stromal fea-tures has not been synthesized. The review will follow PRISMA. PubMed/MEDLINE, Embase, Scopus, and Web of Science will be searched from inception using terms for breast cancer, postpar-tum status, lactation, involution, prognosis, and tumor microenvironment. Eligible studies will be observational (cohort, case–control, cross-sectional) studies of women with breast cancer defining a postpartum subgroup (by time since last childbirth, parity, lactation, or weaning), including a com-parator (nulliparous women or longer birth interval), and reporting at least one prognostic outcome (overall, distant metastasis-free, or disease-free survival, or recurrence), an aggressive clinicopatho-logical feature, molecular/immune profile, or a treatment response. We will exclude experimental studies without human endpoints, risk-factor/incidence studies, reviews, and case reports. Two re-viewers will independently screen, extract data, and assess risk of bias using the Newcastle–Ottawa Scale. If at least five studies report comparable hazard ratios for the same exposure–outcome pair-ing, we will perform a random-effects meta-analysis using restricted maximum likelihood; if 3–4 studies are available, a fixed-effect meta-analysis will be considered as a sensitivity analysis. If fewer than three studies are available, findings will be synthesized narratively. Heterogeneity will be assessed with I² and Cochran’s Q, with I² informing interpretation rather than model choice. | ||
| Keywords | ||
| Breast Neoplasms; Survival Analysis; Postpartum Period; Lactation; Parity | ||
| References | ||
|
| ||
|
Statistics Article View: 83 PDF Download: 29 |
||